NRIXNurix Therapeutics, Inc.

Healthcare

$25.33+152% 1Y

$25.33

$9.8452 weeks$27.79

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap vs its sector.

2 good, 1 without data

What the price assumes~−8% a year

Priced for a decline (~−8% a year). The price demands less than its three-year revenue growth of 117% a year, expectations look modest.

Vs sector (EV/EBIT)8.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Aug 31, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 87% of the market

FCF yieldtop 7% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What NRIX's price assumes

Nurix Therapeutics, Inc. trades at 11.0× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.

11.0

Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group

Price / sales: 3.94
Price / sales · today's price, trailing year to Aug 31, 2026
Free cash flow yield: 13%
Free cash flow yield · Biotechnology median 4.3%
Growth the price implies: −7.7%
Growth the price implies · The price pays for −7.7% free cash flow growth a year for a decade; revenue has grown 117% a year over the last three.